Acarix AB (publ) publishes Year-End Report 2019 Malmö, January 20, 2020 Successful rights issue enables increased focus on strategic initiatives The fourth quarter of 2019 was eventful, and we had the opportunity to see pr...

Press release Malmö, Sweden February 18, 2020 First patient enrolled in the new clinical study FILTER-SCAD targeting 2,000 patients Acarix AB (publ) today announced the initiation of the randomized, multi-center clinical study FILTER-SC...

Press release Malmö, Sweden January 14, 2020 First patients with the CADScor®System in the UK Acarix AB (publ) (ACARIX: FN Stockholm) today announced the first commercial usage of the CADScor®System in the UK.  </s...

Press release Malmö, Sweden 16 December, 2019 Acarix submits FDA application Acarix AB (publ) (ACARIX: FN Stockholm) today announced the submission of a De Novo application to the American Food and Drug Administration (FDA) for the CADScor® System in preparation of a US ...

Malmö, November 14, 2019 Acarix finalized a rights issue to finance further market expansion In September we announced a rights issue in order to be able to further develop our product offering and to intensify our international investments. Dur...

Press release Malmö, 30 October 2019 Inside informationAcarix AB Acarix announce final outcome in rights issue Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of 34,541,0...

Press release Malmö, 9 October 2019 The subscription period in Acarix' rights issue commence today The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 1...

Press release Malmö, 30 September 2019 Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authori...